卵巢储备功能下降 中国就医指南

Diminished Ovarian Reserve (DOR) is a clinical condition characterized by a reduction in the quantity and/or quality of ovarian follicles, leading to impaired reproductive potential. It reflects an early decline in ovarian function—distinct from natural menopause—but often precedes premature ovarian insufficiency (POI). Pathogenically, DOR arises from accelerated follicular atresia, genetic abnormalities (e.g., FMR1 premutation, Turner syndrome mosaicism), iatrogenic causes (chemotherapy, pelvic radiation, or ovarian surgery), autoimmune dysfunction, or idiopathic mechanisms involving mitochondrial dysfunction, oxidative stress, and dysregulated apoptosis in granulosa cells. Unlike polycystic ovary syndrome (PCOS) or hypothalamic amenorrhea, DOR is primarily a quantitative and qualitative biomarker issue—evidenced by elevated basal FSH (>10 IU/L), low anti-Müllerian hormone (AMH < 1.1 ng/mL), and reduced antral follicle count (AFC < 5–7 per ovary)—rather than a hormonal imbalance disorder. Epidemiologically, DOR affects approximately 10–15% of women seeking fertility care globally; prevalence rises sharply after age 35, with up to 30% of women aged 40+ exhibiting biochemical signs of diminished reserve. Risk factors include advanced maternal age (strongest modifiable risk), smoking, prior gonadotoxic exposure, endometriosis (especially stage III/IV with ovarian involvement), autoimmune thyroiditis, and family history of early menopause. Importantly, DOR is not synonymous with infertility—it indicates reduced odds per cycle but does not preclude spontaneous conception, particularly in younger patients with preserved oocyte quality. Quality of life impact extends beyond fertility concerns: women with DOR frequently report heightened anxiety, depression, grief over perceived biological time loss, marital strain, and diminished self-worth tied to reproductive identity. Many experience diagnostic delays due to normal menstrual cyclicity masking underlying reserve decline, resulting in late-stage emotional and financial burden. Early recognition via AMH/AFC/FSH screening—especially before elective fertility preservation—is critical for personalized counseling, timely intervention (e.g., IVF with PGT-A), and psychosocial support integration. Multidisciplinary management in reproductive endocrinology emphasizes realistic expectation-setting, shared decision-making, and holistic care addressing both physiological and existential dimensions of reproductive aging.

# 卵巢储备功能下降（DOR）治疗方案与费用明细

一、非手术/保守治疗

• •适用人群：AMH 0.5–1.1 ng/mL、AFC 5–7枚、FSH <10 IU/L，有自然妊娠意愿者
• •方案与费用（公立三甲医院，RMB）：

- 促排卵联合方案：来曲唑＋hMG微刺激（3个周期）：9,600–14,500元（含B超监测12次、E₂/P/FSH/LH动态检测、药物费） - 卵巢功能保护干预：DHEA（25mg/d×3月）＋生长激素预处理（7天）：12,000–18,000元（含GH注射剂、IGF-1检测、肝肾功能监测）

二、微创介入治疗

• •适用人群：AMH <0.5 ng/mL、既往促排卵反应差、无禁忌证者
• •方案与费用：

三、特殊复杂情况方案

• •耐药型DOR（≥3周期微刺激失败）：GnRH-a激动剂降调节后PPOS方案（含地屈孕酮+HCG双触发）：16,800–24,000元
• •合并早发性卵巢功能不全（POI）：激素替代治疗（HRT）联合IVF-ICSI：48,000–72,000元/周期（含胚胎培养、玻璃化冻存、解冻移植）

四、方案快速选择指南

• •预算≤1万元：首选中药+营养支持+自然试孕监测
• •预算2–4万元：推荐微刺激促排或PRP介入
• •急迫生育需求/高龄（≥38岁）：直接启动IVF-ICSI，避免反复无效促排